[go: up one dir, main page]

NI200700242A - Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos. - Google Patents

Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos.

Info

Publication number
NI200700242A
NI200700242A NI200700242A NI200700242A NI200700242A NI 200700242 A NI200700242 A NI 200700242A NI 200700242 A NI200700242 A NI 200700242A NI 200700242 A NI200700242 A NI 200700242A NI 200700242 A NI200700242 A NI 200700242A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
biosynthesis
leucotriens
tiadiazol
aromatic ring
Prior art date
Application number
NI200700242A
Other languages
English (en)
Inventor
Marc Blouin
Erich L Grimm
Yves Gareau
Marc Gagnon
Helene Juteau
Sebastien Laliberte
Bruce Mackay
Richard Friesen
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200700242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of NI200700242A publication Critical patent/NI200700242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención provee compuestos de la fórmula (Ia) los cuales son inhibidores de biosíntesis de leucotrienos, donde X es O ó S, Y es O, S, -NR6, -CHR7- ó -NR8-C(O)- y A se selecciona de un anillo aromático heterocíclico de 5 miembros, un anillo aromático heterocíclico de 6 miembros, un sistema de anillo aromático naftelenílico o heterobicíclico, fenilo y bencilo. A está opcionalmente mono-o-di-sustituida. Los compuestos de la fórmula (Ia) son útiles como agentes antiatereosclerótico, antiasmáticos, antialérgicos, antiinflamatorios y citoprotectores.
NI200700242A 2005-03-23 2007-09-20 Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos. NI200700242A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66431705P 2005-03-23 2005-03-23

Publications (1)

Publication Number Publication Date
NI200700242A true NI200700242A (es) 2008-05-13

Family

ID=37023348

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700242A NI200700242A (es) 2005-03-23 2007-09-20 Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos.

Country Status (26)

Country Link
US (3) US20090227638A1 (es)
EP (1) EP1869031B1 (es)
JP (2) JP4109316B1 (es)
KR (1) KR20070113259A (es)
CN (2) CN101146802A (es)
AR (1) AR055041A1 (es)
AU (1) AU2006227524B2 (es)
BR (1) BRPI0609687A2 (es)
CA (1) CA2600727C (es)
CR (1) CR9442A (es)
DO (1) DOP2006000069A (es)
EA (1) EA012704B1 (es)
ES (1) ES2394179T3 (es)
GT (1) GT200600117A (es)
IL (1) IL185724A0 (es)
MA (1) MA29398B1 (es)
MX (1) MX2007011638A (es)
MY (1) MY142105A (es)
NI (1) NI200700242A (es)
NO (1) NO20075384L (es)
PA (1) PA8667201A1 (es)
PE (1) PE20061328A1 (es)
TN (1) TNSN07348A1 (es)
TW (1) TWI321130B (es)
WO (1) WO2006099735A1 (es)
ZA (1) ZA200707385B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
JP2009510132A (ja) * 2005-10-05 2009-03-12 メルク フロスト カナダ リミテツド ロイコトリエン生合成の阻害剤としての置換キノリン
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
AR068498A1 (es) * 2007-09-27 2009-11-18 Merck & Co Inc Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AU2011338561A1 (en) 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
HRP20180970T1 (hr) 2010-12-07 2018-08-10 Amira Pharmaceuticals, Inc. Policiklični lpa1 antagonist i njegove primjene
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
CN102924442B (zh) * 2012-11-15 2014-10-29 沈阳药科大学 含有噻唑环的色满类化合物及其类似物和医药用途
CN103304556B (zh) * 2013-06-21 2016-06-01 天津药物研究院有限公司 含有苯并吡喃的希夫碱类化合物、其制备方法和用途
EP3795568A1 (en) 2015-03-06 2021-03-24 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CA2999200C (en) * 2015-09-24 2021-03-30 Guizhou Bailing Group Pharmaceutical Co., Ltd. 4-substituted coumarin derivatives and preparation methods and uses thereof
AU2017324445A1 (en) 2016-09-07 2019-04-11 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
JP7097874B2 (ja) 2016-09-07 2022-07-08 ファーマケア，インク． リシルオキシダーゼ様２阻害剤の使用
CN108658962B (zh) * 2017-03-30 2021-10-01 复旦大学 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途
CN111116506B (zh) * 2019-12-31 2024-03-08 浙江大学衢州研究院 一种芳巯基二唑类衍生物的合成方法
CN113149979B (zh) * 2021-03-05 2022-11-25 朗捷睿(苏州)生物科技有限公司 一种8-(苯并噻唑酰胺)取代香豆素类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3834860A1 (de) * 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE4235603A1 (de) 1992-10-22 1994-04-28 Basf Ag Arylalkoxythiocumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
US5424320A (en) 1993-06-23 1995-06-13 Merck Frosst Canada, Inc. Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US6265421B1 (en) 1997-06-25 2001-07-24 Orion Corporation Phospholamban inhibitors and a method for increasing coronary flow
US6538022B1 (en) * 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
US5968959A (en) 1997-12-12 1999-10-19 Orion Corporation Method for the prevention and treatment of stunned myocardium
CA2429008A1 (en) 2000-07-13 2003-01-09 Takeda Chemical Industries, Ltd. Lipid-rich plaque regressing agents
AU2002221116A1 (en) 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
CA2527769A1 (en) * 2003-06-11 2004-12-16 Merck Frosst Canada Ltd. 7- (1, 3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Also Published As

Publication number Publication date
BRPI0609687A2 (pt) 2010-04-20
JP2008101010A (ja) 2008-05-01
CN101146802A (zh) 2008-03-19
JP4109316B1 (ja) 2008-07-02
EA200702058A1 (ru) 2008-02-28
PE20061328A1 (es) 2007-01-13
NO20075384L (no) 2007-11-30
TW200700414A (en) 2007-01-01
CA2600727A1 (en) 2006-09-28
CA2600727C (en) 2011-06-14
IL185724A0 (en) 2008-01-06
TNSN07348A1 (en) 2008-12-31
MX2007011638A (es) 2007-11-14
US20070149579A1 (en) 2007-06-28
MA29398B1 (fr) 2008-04-01
DOP2006000069A (es) 2006-09-30
WO2006099735A1 (en) 2006-09-28
ES2394179T3 (es) 2013-01-23
EP1869031A4 (en) 2011-02-09
TWI321130B (en) 2010-03-01
CN102627638A (zh) 2012-08-08
US20090030048A1 (en) 2009-01-29
CR9442A (es) 2008-01-21
AU2006227524B2 (en) 2011-06-30
JP5207711B2 (ja) 2013-06-12
EP1869031B1 (en) 2012-08-08
JP2008533179A (ja) 2008-08-21
US20090227638A1 (en) 2009-09-10
GT200600117A (es) 2007-01-19
ZA200707385B (en) 2010-01-27
AU2006227524A1 (en) 2006-09-28
KR20070113259A (ko) 2007-11-28
PA8667201A1 (es) 2006-10-13
MY142105A (en) 2010-09-15
AR055041A1 (es) 2007-08-01
EA012704B1 (ru) 2009-12-30
EP1869031A1 (en) 2007-12-26
US7553973B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
NI200700242A (es) Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos.
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
MX2010000658A (es) Derivados de pirimidina 934.
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ECSP109932A (es) Compuestos de biciclolactama sustituida
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CR9690A (es) 3-acilaminobenzanilidas insecticidas
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
DE602005013272D1 (de) Diphenyl-substituierte alkane als flap-inhibitoren
UA107689C2 (xx) ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
MX2010001093A (es) Herbicidas novedosos.
CY1115256T1 (el) Φαρμακευτικες ενωσεις
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
CO6551700A2 (es) Fungicidas de azolil benceno heterobiciclico- sustituidos
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
BRPI0512843A (pt) inibidores de quinolina
ATE421505T1 (de) 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
BRPI0414972A (pt) derivados de imidazopiridinas como inibidores de no-sintase induzìvel
BRPI0414873A (pt) derivados de imidazopiridina como inibidores de no-sintase induzìveis
DE602004002464D1 (de) IMIDAZOi4,5-BöCHINOLINDERIVATE UND IHRE VERWENDUNG ALS INHIBITOREN DER INDUZIERBAREN NO-SYNTHASE
EA200700254A1 (ru) Димерные производные пипередина